INMB · NASDAQ
Inmune Bio (INMB) Stock Price & Fundamentals
Inmune Bio (INMB) closed at $318.64 on Oct 9, 2026, up 1.34% from the previous close of $314.43.
Share price, past year
1Y +8.18%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $318.64 |
| Sep 30, 2026 | $318.68 |
| Aug 31, 2026 | $337.35 |
| Jul 31, 2026 | $318.31 |
| Jun 30, 2026 | $317.22 |
| May 29, 2026 | $317.11 |
| Apr 30, 2026 | $309.67 |
| Mar 31, 2026 | $311.93 |
| Feb 27, 2026 | $306.33 |
| Jan 30, 2026 | $286.67 |
| Dec 31, 2025 | $308.14 |
| Nov 28, 2025 | $308.41 |
| Oct 31, 2025 | $299.63 |
Key statistics
- Market cap
- $8.81B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.63
- Revenue (TTM)
- —
- Net income (TTM)
- −$18.42M
- Shares outstanding
- 27.7M
- Dividend yield
- —
- 52-week range
- $286.67 – $350.56
Inmune Bio's market cap is $8.81B, based on a share price of $318.64 and 27.7M shares outstanding as of Jun 30, 2026.
Financials
Inmune Bio reported revenue of $50.00K for fiscal 2025, up 257.14% from fiscal 2024.
Inmune Bio reported a net loss of $45.93M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $50.00K | +257.1% | −$45.93M | −91,866.0% | −$1.86 | −$23.62M |
| FY2024ended Dec 31, 2024 | $14.00K | −91.0% | −$42.08M | −300,585.7% | −$2.11 | — |
| FY2023ended Dec 31, 2023 | $155.00K | −58.6% | −$30.01M | −19,360.0% | −$1.67 | — |
| FY2022ended Dec 31, 2022 | $374.00K | +106.6% | −$27.30M | −7,299.2% | −$1.52 | — |
| FY2021ended Dec 31, 2021 | $181.00K | +1,545.5% | −$30.34M | −16,762.4% | −$1.88 | — |
| FY2020ended Dec 31, 2020 | $11.00K | — | −$12.10M | −109,990.9% | −$1.01 | — |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$12.44M | — | −$1.43 | — |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$831.49K | — | −$0.13 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2025ended Mar 31, 2025 | $50.00K | −$9.74M | −$0.43 |
| Q1 FY2024ended Mar 31, 2024 | $14.00K | — | — |
| Q4 FY2023ended Dec 31, 2023 | $28.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $43.00K | — | — |
| Q2 FY2023ended Jun 30, 2023 | $46.00K | — | — |
| Q1 FY2023ended Mar 31, 2023 | $38.00K | — | — |
| Q4 FY2022ended Dec 31, 2022 | $97.00K | — | — |
| Q3 FY2022ended Sep 30, 2022 | $98.00K | — | — |
Company profile
- Name
- Inmune Bio, Inc.
- Ticker
- INMB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 225 Ne Mizner Blvd, Suite 640, Boca Raton, FL 33432
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001711754
Recent SEC filings
- Sep 14, 2026
- Aug 6, 2026
- Jul 31, 2026
- Jul 1, 2026
- Jun 23, 2026
- Jun 17, 2026
- Jun 2, 2026
- May 14, 2026
Frequently asked questions
What is Inmune Bio's stock price?
Inmune Bio (INMB) closed at $318.64 on Oct 9, 2026, up 1.34% from the previous close of $314.43.
What is Inmune Bio's market cap?
Inmune Bio's market cap is $8.81B, based on a share price of $318.64 and 27.7M shares outstanding as of Jun 30, 2026.
How much revenue does Inmune Bio make?
Inmune Bio reported revenue of $50.00K for fiscal 2025, up 257.14% from fiscal 2024.
Does Inmune Bio pay a dividend?
Inmune Bio's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Inmune Bio, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures